CoLucid Pharmaceuticals, which is developing drugs to combat central nervous systems disorders, has closed on $1.5 million in new funding.

The funds came in the form of debt and warrants, according to a filing with the SEC.

CoLucid, which has raised more than $41 million in venture funding since its launch in 2005, disclosed a $2 million round of funding in February. The firm wants to raise $9 million total in the current round, according to the filing.

Pappas Ventures, which is based in the Triangle, launched the company in 2005.

Care Capital led a $25 million B round in 2008 as a new investor. Also participating were Domain Associates, Pearl Street Venture Funds and Triathlon Medical Ventures.

CoLucid is developing a migraine compound called COL-144. CoLucid is also pursuing developing of potential drugs to treat neurological and psychiatric disorders.

CoLucid touts its compound as a “first-in-class neurally acting anti-migraine agent” that avoids side effects of blood vessel constriction associated with other migraine therapies.

Read the SEC filing here.

Get the latest news alerts: Follow WRAL Tech Wire at Twitter.